Natural Language Generation (NLG) company and document drafting technology supplier Litera have announced a partnership with Yseop to provide life science companies with more efficient and effective management of regulatory compliance processes.
Bringing a new drug to market takes between 10 and 15 years and costs between $1.5 and $2 billion. In a context of heightened regulatory scrutiny and obligations, relying on manual reporting systems and complex, resource-intensive and time-consuming processes, can jeopardise the whole investment.
Litera is committed to accelerating the creation, review, formatting, and standardisation of documents to offer the fastest path to compliance, with a dedicated offering for regulatory, medical affairs, and clinical operations specialists. Its solution portfolio (DocXtools for Life Sciences, Change-Pro Premier, and Content Companion) offers a best-of-breed combination to streamline and accelerate high-quality submissions.
Matt Miller, Litera director of product management said: “Patients are waiting. This is the most important driving factor we bear in mind when working with life science companies. We are always looking for technologies that can help them complete submissions faster. Yseop’s expertise in AI-powered intelligent automation blends in well with our document processing technology and we are proud to be able to work collaboratively on offering the best approach to streamline regulatory submission.”
Working closely with some of the global leading pharmaceutical companies, Yseop has provides automated reporting solutions for medical writers, built on advanced artificial intelligence NLG technology. By automating some of the manual reporting sections needed to ensure compliance and safety, Yseop’s NLG solution helps pharmaceutical companies save time and money and get drugs to market faster.
Emmanuel Walckenaer, CEO of Yseop, said: “NLG offers this unique ability to help scale human expertise and regulatory submission is one of the areas where the benefits it delivers proves the more valuable. We share with Litera the urge to provide Life Sciences company with the best technology available. We are delighted to enrich our respective ecosystem and are eager to have our joint clients combine our technologies and achieve new levels of regulatory compliance efficiency.”
